Effect of pluronic L-81 on intestinal lipoprotein secretion in the rat.
The hydrophobic nonionic detergent Pluronic L-81 has been shown to lower plasma very-low- and low-density lipoprotein cholesterol, thus preventing diet-induced atherogenesis. The major effect of this agent is a pronounced interference with intestinal lipid metabolism. For studying mesenteric lymph lipoproteins during detergent exposure, a combined micromorphological and biochemical assessment of mucosa and lymph during steady-state lipid absorption was performed. Pluronic L-81 was infused intraduodenally at a constant rate in combination with mixed micellar solutions or saline in mesenteric lymph fistula rats. Pluronic L-81 impairs transepithelial lipid flux during fat absorption, trapping export lipids within the enterocytes and leading to a cytosolic and endoplasmic reticulum lipid accumulation sparing the Golgi region. Pluronic L-81 markedly (P < 0.001) reduces mesenteric triglyceride, phospholipid, and total cholesterol secretion almost exclusively by a reduction of chylomicron formation. Chylomicron and very-low-density lipoprotein lipid composition was only insignificantly altered, except for somewhat higher phospholipid/triglyceride ratios. The chylomicron apoprotein pattern was almost unaffected. Thus, chylomicron formation decreased dramatically without major compositional alterations. The reduction of lipid and apoprotein secretion without particle augmentation is not in favour of a selective interference of Pluronic L-81 with intestinal apoprotein B-48 secretion.
Pidlich
J
J
Department of Gastroenterology, University of Vienna, Medical School, Austria.
Renner
F
F
Ellinger
A
A
Hüttinger
M
M
Pavelka
M
M
Gangl
A
A
D000818:Animals; D001059:Apoproteins / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism; D002914:Chylomicrons / Q000378:metabolism; D005215:Fasting; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D007421:Intestine, Small / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D050356:Lipid Metabolism; D008074:Lipoproteins / Q000737:chemistry / Q000378:metabolism*; D008196:Lymph / Q000378:metabolism; D008297:Male; D008643:Mesentery; D010743:Phospholipids / Q000378:metabolism; D011060:Poloxalene / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013501:Surface-Active Agents / Q000494:pharmacology*; D014280:Triglycerides / Q000378:metabolism
D001059:Apoproteins; D002914:Chylomicrons; D008074:Lipoproteins; D010743:Phospholipids; D013501:Surface-Active Agents; D014280:Triglycerides; D011060:Poloxalene; D002784:Cholesterol